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comprehensive molecular characteriza-
tion, as beautifully illustrated in the Read
et al. study, along with similar definition
of normal progenitor lineages should
allow TPC categorization and ultimately
a fuller understanding of the disease for
design of individualized treatments.
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g-secretase inhibitors block the activation of NOTCH1 but have limited activity against T cell acute lympho-
blastic leukemia (T-ALL) and cause severe gastrointestinal toxicity. In a recent study, Real et al. show that
a potent g-secretase inhibitor potentiates the cytotoxicity of dexamethasone against glucocorticoid-resis-
tant T-ALL cells, while dexamethasone abrogates the gastrointestinal toxicity induced by the g-secretase
inhibitor.T cell acute lymphoblastic leukemia
(T-ALL), a clonal malignant disorder of
immature T cells, represents 10%–15%
of childhood and 25% of adult ALL cases.
Although intensive chemotherapy has
done much to improve prognosis for this
disease, as many as 30% of childhood
cases and approximately 50% of adult
cases will relapse. Remarkable progress
in understanding the genetic mechanisms
underlying T-ALL pathogenesis has
opened the way for the development of
molecular targeted therapy. It is now clear
that genetic abnormalities involving T cell
receptor genes, basic helix-loop-helix
genes (e.g., TAL1, TAL2, LYL1, MYC),
cysteine-rich LIM domain-containing
genes (LMO1, LMO2), or homeodomain
genes (e.g., HOX11/TLX1, HOX11L2/TLX3, the HOXA gene cluster) can partici-
pate in the transformation of normal
thymocytes by blocking differentiation.
Abnormalities of a different group of genes
(e.g., CDKN2A/2B, CCND2, LCK, RAS,
PTEN, ABL1, JAK2, FLT3) appear to
increase self-renewal, alter responses to
extracellular signals, or impose resistance
to apoptosis (Pui et al., 2008; Van Vlier-
berghe et al., 2008).
NOTCH1 encodes a heterodimeric
receptor that regulates normal T cell devel-
opment beginning as early as the commit-
ment of multipotent hematopoietic
progenitors to the T cell lineage (Figure 1).
Activating mutations of NOTCH1 repre-
sent one of the most common genetic
abnormalities in T-ALL. Indeed, 60% of
T-ALL cases possess such mutationsCancer Cell(Weng et al., 2004; van Grotel et al., 2008;
Asnafi et al., 2008). Among them, acti-
vating mutations of theNOTCH1 heterodi-
merization domain or juxtamembrane
extracellular region induce ligand-inde-
pendent activation of the receptor. Trun-
cating mutations of the COOH-terminal
PEST domain of the intracellular region,
on the other hand, extend NOTCH1
signaling by removing the Cdc phospho-
degron domains and preventing the pro-
teasome-mediated degradation of the
intracellular domains of the receptor (Palo-
mero and Ferrando, 2008). One of the
proteins that binds to theCdc phosphode-
gron and primes the intracellular subunit
for degradation is the F box protein
FBXW7. Thus, it is not surprising that
mutations in FBXW7 can also extend15, February 3, 2009 ª2009 Elsevier Inc. 85
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20% of T-ALL cases have two coexisting
lesions that activate NOTCH1 (Weng
et al., 2004; van Grotel et al., 2008; Asnafi
et al., 2008).
Theprecisemechanismsbywhichaber-
rant NOTCH1 signaling drives the patho-
genesis of T-ALL are still unclear but
probably entail constitutive expression of
oncogenic responder genes, such as
MYC, and activation of other signaling
pathways (e.g., the phosphatidylinositol
3-OH kinase [PI3K]/AKT/mammalian
target of rapamycin [mTOR] pathway and
the NF-kB pathway) (Palomero and Fer-
rando, 2008). Because g-secretase is
required for NOTCH1 activation (Figure 1),
inhibitors of this proteolytic step might
abrogate the function of oncogenic
NOTCH1 and suppress T-ALL cell growth.
Indeed, g-secretase inhibitors have been
shown to induce cell-cycle arrest at
G0/G1, decrease cell viability, and cause
some apoptosis in a subset of T cell lines
carrying NOTCH1-activating mutations
(Weng et al., 2004; Lewis et al., 2007).
However, clinical development of g-secre-
tase inhibitors for the treatment of T-ALL
has so far been unsuccessful because of
their limited antileukemic activity and their
severe gastrointestinal toxicity resulting
from massive conversion of proliferative
intestinal crypt cells intopostmitotic goblet
cells in the gut (van Es et al., 2005; Dean-
gelo et al., 2006).
Abandoning g-secretase inhibitors as
promising candidates for the treatment of
T-ALL may be premature, as Real et al.
(2009) present data in a recent issue of
Nature Medicine indicating that these
agents might be more effective and less
toxic if they were given in combination
with glucocorticoids. The authors found
that a potent g-secretase inhibitor
(Compound E) and dexamethasone (a
glucocorticoid widely used to treat
T-ALL) have synergistic, though modest,
activity against three glucocorticoid-resis-
tant T-ALL cell lines with activated
NOTCH1 and in two of three glucocorti-
coid-resistant primary human T-ALL
samples. There was no evidence of such
Figure 1. Schematic Representation of the NOTCH1 Signaling Pathway and Its Interaction
with Dexamethasone Treatment
ThematureNOTCH1 receptor is a heterodimeric single-pass transmembrane receptor consisting of a non-
transmembrane extracellular subunit and a transmembrane intracellular subunit noncovalently joined via
heterodimerization domains (HD). The receptors become activated when ligands of the Delta/Serrate/
Lag2 family of proteins bind to the extracellular portion of themolecule. This interaction triggers a cascade
of proteolytic cleavages, first by ADAM10 and subsequently by the g-secretase complex, resulting in the
release of the intracellular domain of NOTCH1 (ICN1). ICN1 translocates to the nucleus to form a complex
with the CSL DNA-binding protein and the MAML1 (mastermind-like protein 1) transcriptional coactivator,
leading to transcriptional activation of a diverse set of responder genes, including theMYC oncogene and
the transcriptional repressor HES1 (hairy and Enhancer of split homolog-1). NOTCH1 signaling is termi-
nated through proteasome-mediated degradation of ICN1 after it is phosphorylated at the COOH-terminal
PEST domain by CDK8. By blocking NOTCH1-HES1 signaling, g-secretase inhibitors restore glucocorti-
coid receptor autoupregulation, resulting in effective upregulation ofBCL2L11, which encodes a BH3-only
protein (BIM) that has been implicated in glucocorticoid-induced cell death. Dexamethasone treatment
induces upregulation of the cyclin D2 gene (CCND2) in the intestinal epithelium, which in turn inhibits
the activation of KLF4 (Kru¨ppel-like factor 4), a transcriptional factor controlled by NOTCH-HES1 signaling
that functions as a negative regulator of the cell cycle required for goblet cell differentiation.86 Cancer Cell 15, February 3, 2009 ª2009 Elsevier Inc.interaction in glucocorticoid-sensitive cell
lines or primary leukemias, nor was there
synergy between Compound E and anti-
leukemic drugs of other classes. Interest-
ingly,CompoundEenhanceddexametha-
sone treatment-induced glucocorticoid
receptor gene (NR3C1) autoupregulation
and expression of the BCL2L11 gene,
which encodes BIM (Figure 1). The upre-
gulation of NR3C1 and the expression of
BIM have been shown to be required for
glucocorticoid-induced cell death. The
authors further demonstrate the thera-
peutic efficacy of Compound E plus dexa-
methasone in leukemia-bearing mice.
Even if g-secretase inhibitors do poten-
tiate glucocorticoid killing of T-ALL cells,
their gastrointestinal toxicity can still be
an obstacle to their routine use in clinical
settings. Real et al. counter this concern
by showing that glucocorticoids can in
fact protect the gut from the deleterious
effects of NOTCH1 inhibition. This effect
appears to be mediated by transcriptional
upregulation of cyclin D2 and suppression
of intestinal goblet cell metaplasia
(Figure 1).
If the data of Real et al. are confirmed in
additional T cell lines and primary clinical
samples, how might g-secretase inhibi-
tors best beexploited in the clinic?Several
studies have suggested that most T-ALL
blasts with NOTCH1 mutations respond
well to glucocorticoid treatment. Among
these, in the largest childhood study, the
82 patients with activating mutations had
significantly better responses to single-
agent prednisone treatment and more
favorable long-term outcomes than did
the other 75 patients without mutations
(Breit et al., 2006). In addition, a recent
study of 141 adult patients with T-ALL
showed that the 88 patients withNOTCH1
and/or FBXW7 mutations had a slightly
more favorable outcome than those
without the mutations (Asnafi et al.,
2008). These results indicate that the
data of Real et al. may be applicable to
only a subset of relapsed T-ALL patients
with acquired resistance to glucocorticoid
therapy. Thus, although NOTCH1 activa-
tion alone does not seem to induce gluco-
corticoid resistance, its inhibition might
enhance glucocorticoid receptor function
in very resistant cases, allowing the cells
to respond to glucocorticoid treatment.
In this regard, the use of high-dose dexa-
methasone significantly improved treat-
ment outcome in patients with T-ALL in
Cancer Cell
Previewsa recent study (Schrappe et al., 2008).
Should future studies demonstrate that
the concomitant use of a NOTCH1 inhib-
itor with glucocorticoids can enhance the
response of resistant leukemia, lower
doses of dexamethasone could be used
to treat such patients, sparing them from
the toxicity of intensified chemotherapy.
The protective effect of glucocorticoid
therapy against the gastrointestinal
toxicity of g-secretase inhibitors might
also renew interest in g-secretase inhibi-
tors as therapy for patients with Alz-
heimer’s disease, for whom the drugs
were first introduced to inhibit the produc-
tion of amyloidogenic b-amyloid peptides.
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